Last updated: April 15, 2026
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the two most common forms of skin cancer, but they behave very differently. BCC grows slowly and almost never spreads beyond the skin, while SCC grows faster and carries a 2–5% risk of spreading to other parts of the body [5]. Both are highly treatable when caught early, with surgical options offering cure rates of 95–99% [2].
BCC (basal cell carcinoma) and SCC (squamous cell carcinoma) are both non-melanoma skin cancers, but they come from different cell types and carry different risks. Understanding BCC vs. SCC — what's the difference and how are they treated — matters because the wrong assumption about one can lead to delayed care for the other.
BCC starts in the basal cells, which sit at the bottom of the epidermis (the skin's outermost layer). These cells normally divide to replace old skin cells. When UV radiation or other damage causes mutations, they can grow uncontrollably — but almost always stay local [5].
SCC starts in squamous cells, which make up most of the upper epidermis. These cells are more exposed to the environment, so they accumulate damage faster. SCC grows more quickly and has a meaningful (though still relatively low) chance of spreading to lymph nodes or distant organs [5].
"BCC is the most common cancer in humans. SCC is the second most common. Together, they account for the vast majority of skin cancer diagnoses worldwide." — Bare Dermatology, March 2026 [5]
Both cancers are most common in:
SCC also has a unique risk factor: it can develop from precancerous lesions called actinic keratoses (rough, scaly patches caused by sun damage). BCC rarely has a clear precursor lesion.
The two cancers look different on the skin, and recognizing those differences can prompt earlier medical evaluation. That said, no visual inspection replaces a biopsy — the only definitive way to diagnose either cancer.
BCC most commonly appears on sun-exposed areas: the face, neck, ears, scalp, and hands. Common presentations include:
BCC subtypes include nodular (most common), superficial, and morpheaform. Each has slightly different visual features and different recurrence risks.
SCC also favors sun-exposed skin but can appear on the lips, inside the mouth, on the genitals, or in scars and chronic wounds. Signs include:
Certain skin growths can mimic or even progress toward SCC. For example, cutaneous horns — unusual projections of compacted keratin — sometimes have SCC at their base and always warrant evaluation. Similarly, Bowen's disease is a form of SCC in situ (confined to the skin's surface) that can progress to invasive SCC if left untreated.
FeatureBCCSCCCell of originBasal cells (lower epidermis)Squamous cells (upper epidermis)Growth rateSlowFasterMetastasis risk<1%2–5%Common locationsFace, nose, ears, scalpFace, lips, ears, hands, genitalsTypical appearancePearly bump, translucent, blood vesselsFirm red nodule, scaly, crustedPrecursor lesionRareActinic keratosis, Bowen's diseaseRisk of recurrenceModerate (varies by subtype)Higher for poorly differentiated tumors
Diagnosis requires a skin biopsy — a tissue sample sent to a pathologist for examination under a microscope. A dermatologist or surgeon will first perform a clinical examination, then choose from several biopsy techniques:
Once the biopsy confirms cancer, the pathology report will include:
For SCC with high-risk features (large size, deep invasion, perineural involvement, or immunosuppressed patient), imaging (CT or PET scan) may be ordered to check for lymph node involvement.
Surgery is the gold standard for treating both BCC and SCC. For most localized tumors, surgical removal offers the best chance of a cure [2].
Mohs surgery is the preferred approach for high-risk BCC and SCC, particularly on the face, ears, nose, and eyelids — areas where preserving healthy tissue matters most. During Mohs:
Why it matters: Mohs achieves cure rates of 98–99% for primary BCC and 94–97% for primary SCC, while sparing the maximum amount of healthy tissue [2]. NCCN guidelines recommend Mohs for high-risk tumors in both categories [2][7].
After BCC removal, recovery is generally straightforward. For a detailed look at what to expect, see this guide to basal cell carcinoma recovery after removal.
For lower-risk tumors in less cosmetically sensitive areas, standard excision with a defined margin (typically 4–6 mm for BCC, 4–10 mm for SCC depending on size and risk) is effective and widely used. Cure rates are approximately 95% for primary tumors [2].
Choose Mohs if: The tumor is on the face, ears, nose, hands, or genitals; it's large (>2 cm); it's recurrent; or the patient is immunosuppressed.
Choose standard excision if: The tumor is on the trunk or extremities, is small and well-defined, and is a primary (not recurrent) lesion.
ED&C involves scraping the tumor with a curette and then burning the base with an electric current. It's used for small, low-risk, superficial BCC on the trunk and extremities. It's not appropriate for SCC due to higher recurrence risk and the inability to assess margins.
Not every patient is a good surgical candidate, and not every tumor requires surgery. Several non-surgical options exist, each with specific indications.
Two topical medications are approved for superficial BCC and, in some cases, SCC in situ:
Common mistake: Using topical therapies for nodular or infiltrative BCC, or for invasive SCC. These tumors extend deeper than topicals can reach, leading to incomplete treatment and higher recurrence.
PDT uses a photosensitizing agent applied to the skin, followed by light activation to destroy cancer cells. It's best for superficial BCC and SCC in situ in patients who can't tolerate surgery. Cosmetic outcomes are often good, but recurrence rates are higher than with surgery [6].
Radiation is an option for patients who cannot undergo surgery — due to age, medical comorbidities, or tumor location. It's also used as adjuvant therapy after surgery when margins are positive and re-excision isn't possible.
Important caveat: Radiation carries a risk of worsening cosmetic outcomes over time, particularly in patients under 55. It's generally not the first choice for younger patients [1].
Liquid nitrogen can freeze and destroy small, superficial, low-risk BCC lesions. Recurrence rates for BCC treated with cryotherapy range from 3.5–16.5%, which is significantly higher than surgical options [2]. It's rarely used for SCC due to the inability to confirm clear margins. For more on how cryotherapy is used for skin lesions, see this overview of cryotherapy for mole removal.
For tumors that can't be treated with surgery or radiation, or that have spread, systemic therapies are now available — and the pipeline is expanding rapidly.
BCC tumors frequently have mutations in the hedgehog signaling pathway. Two FDA-approved drugs target this pathway:
Both drugs have significant side effects (muscle cramps, hair loss, taste changes) and are not appropriate for most early-stage BCC. They're reserved for patients who aren't candidates for surgery or radiation.
In the pipeline: Stamford Pharmaceuticals' SP-002, an adenovirus-based biologic for locally advanced BCC, has a Phase IIb trial underway, with Phase III studies expected to begin in late 2025 or early 2026 [3]. Sirnaomics' STP705 is another pipeline candidate being watched closely [3].
SCC has benefited from the immunotherapy revolution more directly than BCC. Several PD-1 inhibitors are now approved or available:
The NCCN 2026 Annual Conference (March 27–29, 2026) discussed evolving clinical insights for BCC and SCC management, reflecting how quickly treatment guidelines are being updated [7].
For a broader look at how skin cancers are classified and treated, see this guide to the 4 main types of skin cancer. Patients concerned about melanoma specifically can also review melanoma surgery and treatment options.
Both cancers worsen over time, but the consequences differ.
Untreated BCC will continue to grow locally, destroying surrounding tissue — cartilage, bone, nerves, and even the eye socket in severe facial cases. Despite its low metastatic rate, locally advanced BCC can cause serious disfigurement and functional loss. It almost never kills, but it can cause significant harm [5].
Untreated SCC carries a real risk of spreading. The 2–5% metastasis rate sounds low, but for high-risk SCC (large tumors, deep invasion, perineural spread, immunosuppressed patients), that risk climbs considerably. Once SCC spreads to lymph nodes, 5-year survival drops significantly [5][10].
The bottom line: Neither cancer should be watched and waited on without a clear plan. Early treatment is far simpler, less costly, and more effective than treating advanced disease.
Treatment doesn't end at surgery. Both BCC and SCC require ongoing monitoring.
Patients who've had one BCC or SCC are at significantly higher risk of developing another. Consistent follow-up is not optional — it's part of the treatment plan.
Q: Is BCC or SCC more dangerous?
SCC is generally more dangerous because it has a higher metastatic rate (2–5% vs. less than 1% for BCC). However, locally advanced BCC can cause serious tissue destruction even without spreading [5].
Q: Can BCC turn into SCC?
No. BCC and SCC are distinct cancer types that arise from different cells. One does not transform into the other. However, a person can develop both cancers independently [5].
Q: How long does it take for BCC or SCC to develop?
Both typically develop over years of cumulative UV exposure. There's no fixed timeline — some lesions appear relatively quickly after significant sun damage, while others take decades to develop.
Q: Is Mohs surgery necessary for every BCC or SCC?
No. Mohs is recommended for high-risk tumors, particularly on the face, ears, nose, and hands, or for recurrent lesions. Low-risk tumors on the trunk or extremities can often be treated with standard excision [2].
Q: Can BCC or SCC be treated with creams alone?
Topical creams like imiquimod or 5-FU are options for superficial BCC and SCC in situ (not invasive SCC). They're not appropriate for nodular, infiltrative, or invasive tumors, which require surgical or systemic treatment [1][6].
Q: What's the cure rate for BCC and SCC?
For primary (first-occurrence) tumors treated with Mohs surgery, cure rates are 98–99% for BCC and 94–97% for SCC. Standard excision achieves approximately 95% for both [2].
Q: Does insurance cover BCC and SCC treatment?
In most cases, yes. Because BCC and SCC are medically diagnosed cancers, treatment is generally covered by health insurance. Coverage details vary by plan and country — confirm with your provider before scheduling.
Q: What's the difference between SCC and melanoma?
SCC arises from squamous cells and is usually slow to spread. Melanoma arises from pigment-producing cells (melanocytes) and is far more aggressive, with a higher metastatic rate and mortality. Melanoma requires different staging and treatment protocols.
Q: Are there any new treatments for BCC or SCC in 2026?
Yes. Cosibelimab (UNLOXCYT) became available in the U.S. in January 2026 for advanced cutaneous SCC [4]. For BCC, Stamford Pharmaceuticals' SP-002 is in Phase IIb trials, with Phase III expected to start in 2026 [3].
Q: Should I see a dermatologist or a surgeon for BCC or SCC?
Both. A dermatologist typically performs the initial evaluation and biopsy. A dermatologic surgeon, plastic surgeon, or Mohs surgeon handles removal. For advanced disease, an oncologist joins the care team.
The core message of BCC vs. SCC — what's the difference and how are they treated — comes down to this: both cancers are common, both are linked to sun damage, and both are highly curable when found early. SCC demands faster action and closer monitoring due to its metastatic potential, while BCC, though slower, can cause serious local damage if ignored.
Actionable next steps:
Patients in the Greater Toronto Area looking for expert evaluation and removal of skin lesions can explore options through The Minor Surgery Center's clinic locations, which offer services in Toronto, Mississauga, Oakville, and beyond. Their board-certified surgeons specialize in skin lesion assessment and removal, including BCC and SCC.
[1] How Is Basal Cell Different From Squamous Cell Carcinoma - https://www.calderminstitute.com/how-is-basal-cell-different-from-squamous-cell-carcinoma/
[2] P161 - https://www.aafp.org/pubs/afp/issues/2012/0715/p161.html
[3] Basal Cell Carcinoma Market Poised For Steady Growth Throughout Forecast Period 20252034 Driven By Novel Drug Approvals And Expanding Patient Pool Delveinsight 302627764 - https://www.prnewswire.com/news-releases/basal-cell-carcinoma-market-poised-for-steady-growth-throughout-forecast-period-20252034-driven-by-novel-drug-approvals-and-expanding-patient-pool--delveinsight-302627764.html
[4] Sun Pharma Announces The Availability Of Cosibelimab Ipdl For Advanced Cutaneous Squamous Cell Carcinoma - https://www.accc-cancer.org/view/sun-pharma-announces-the-availability-of-cosibelimab-ipdl-for-advanced-cutaneous-squamous-cell-carcinoma
[5] Basal Cell Carcinoma Vs Squamous Cell Carcinoma - https://www.barederm.com/blog-post/basal-cell-carcinoma-vs-squamous-cell-carcinoma/
[6] Treating - https://www.cancer.org/cancer/types/basal-and-squamous-cell-skin-cancer/treating.html
[7] Developing Clinical Insight Professional Competencies And Strategic Awareness Nccn 2026 Annual Conference - https://www.accc-cancer.org/view/developing-clinical-insight-professional-competencies-and-strategic-awareness-nccn-2026-annual-conference
[9] Basal Cell Carcinoma Versus Squamous Cell Carcinoma - https://sensushealthcare.com/basal-cell-carcinoma-versus-squamous-cell-carcinoma/
[10] 418 Treatment Update Basal Cell And Squamous Cell Cancer - https://www.cancercare.org/publications/418-treatment_update_basal_cell_and_squamous_cell_cancer
